Older patient age is associated with lower survival at 6 months after treatment of SR-aGVHD. (A) The graph shows the correlation of median patient age with 6-month survival in retrospective and prospective studies of interventions to treat SR-aGVHD. Studies included ≥30 patients, were published from 2012 to the present, and were not included in the 2012 ASBMT Guideline (supplemental Table 1, available on the Blood Web site). The blue line and red oval are provided to help visualize the correlation and identify possible outliers with better than expected results, and they do not represent the results of a statistical analysis. (B) The graph highlights studies that tested ECP, ruxolitinib, or CD-25-specific antibody and included ≥30 patients. The dashed blue line and dashed red oval replicate the line and oval from Figure 3A.